# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-21-015985
Filing Date
2021-05-05
Accepted
2021-05-05 17:12:03
Documents
7
Period of Report
2021-06-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | nc10023502x1_def14a.htm | DEF 14A | 665333
2 |  | logo_aquestive-reg.jpg | GRAPHIC | 54294
3 |  | logo_aquestive-regx1.jpg | GRAPHIC | 43389
4 |  | nc10023502x1_pc01.jpg | GRAPHIC | 739456
5 |  | nc10023502x1_pc02.jpg | GRAPHIC | 634798
6 |  | sig_keithjkendall.jpg | GRAPHIC | 18982
7 |  | sig_lorijbraenderx1.jpg | GRAPHIC | 26060
| Complete submission text file | 0001140361-21-015985.txt |  | 2754506

Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38599 | Film No.: 21894497
SIC: 2834 Pharmaceutical Preparations